Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

SELL
$9.77 - $21.47 $884,771 - $1.94 Million
-90,560 Reduced 60.7%
58,624 $863 Million
Q4 2023

Feb 14, 2024

BUY
$4.48 - $10.11 $668,344 - $1.51 Million
149,184 New
149,184 $1.44 Billion

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $200M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Susquehanna Portfolio Strategies, LLC Portfolio

Follow Susquehanna Portfolio Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna Portfolio Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna Portfolio Strategies, LLC with notifications on news.